Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of “Moderate Buy” by Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $18.00.

Several research analysts have issued reports on the company. Stephens reissued an “overweight” rating and issued a $15.00 target price on shares of Candel Therapeutics in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Wednesday, January 21st. Canaccord Genuity Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Candel Therapeutics in a research note on Friday, March 13th. Zacks Research raised shares of Candel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, March 9th. Finally, Citigroup cut their target price on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, March 13th.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, Director Paul B. Manning acquired 550,458 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was purchased at an average price of $5.45 per share, with a total value of $2,999,996.10. Following the transaction, the director directly owned 2,763,527 shares in the company, valued at approximately $15,061,222.15. The trade was a 24.87% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 16.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its stake in shares of Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after acquiring an additional 4,439 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Candel Therapeutics during the fourth quarter worth about $51,000. Tower Research Capital LLC TRC raised its stake in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after purchasing an additional 7,527 shares during the period. Invesco Ltd. bought a new stake in Candel Therapeutics during the 1st quarter valued at approximately $59,000. Finally, ProShare Advisors LLC purchased a new position in Candel Therapeutics in the 4th quarter worth approximately $59,000. 13.93% of the stock is owned by institutional investors.

Candel Therapeutics Price Performance

NASDAQ CADL opened at $5.17 on Wednesday. The business’s fifty day moving average price is $5.58 and its 200-day moving average price is $5.41. The stock has a market capitalization of $283.83 million, a price-to-earnings ratio of -7.28 and a beta of -0.91. The company has a debt-to-equity ratio of 0.91, a current ratio of 13.49 and a quick ratio of 13.49. Candel Therapeutics has a 1-year low of $4.25 and a 1-year high of $9.08.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.30). On average, equities analysts predict that Candel Therapeutics will post -1.47 earnings per share for the current year.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.